Click here to return to the Reference Table

Category: Hematopoietic Malignancies
Cancer type: Lymphomas
Descriptor: Therapeutic Development

Reference Number: 682
Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, DastrĂ¹ W, Christensen JG, Crepaldi T, Ponzetto C. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res. 14, 2220-6 (2008)
PubMed link      E-mail link

Reference Number: 710
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6, 3314-22 (2007)
PubMed link      E-mail link

Reference Number: 713
Ria R, Cirulli T, Giannini T, Bambace S, Serio G, Portaluri M, Ribatti D, Vacca A, Dammacco F. Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. Clin Exp Med. 8,141-5 (2008) Epub 2008 Sep 13
PubMed link      E-mail link

Reference Number: 802
Uddin S, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P, Al-Kuraya KS. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest. 90, 1346-56 (2010)
PubMed link      E-mail link

Reference Number: 1539
Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res. 201, 197-205 (2014)
PubMed link      E-mail link

Reference Number: 1803
Dai L, Trillo-Tinoco J, Cao Y, Bonstaff K, Doyle L, Del Valle L, Whitby D, Parsons C, Reiss K, Zabaleta J, Qin Z. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood. 126, 2821-31 (2015)
PubMed link      E-mail link